Cannabinoids, Learning, and Memory (THC-Memory)

Yale University

Status and phase: Active, not recruiting; Phase 1

Conditions: Psychotic Disorders; Cannabis

Treatments: Drug: Placebo; Drug: THC

Study type: Interventional

Funder types: Other

Identifiers

NCT02407808

No NIH funding (Other Identifier)

1501015211

Details and patient eligibility

About

The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.

Full description

This study will be achieved by studying the acute effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis and a cannabinoid-1 receptor (CB1R) agonist, on a wide range of memory tasks in healthy human subjects.

Enrollment: 80 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Men and women aged 18 and 55 years (extremes included) on day of first dosing
• Exposed to cannabis at least once in their lifetime

Exclusion criteria

• Cannabis naive
• Positive pregnancy screen during screening
• Hearing deficits

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

80 participants in 2 patient groups, including a placebo group

THC

Active Comparator group

Description:

Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes.

Treatment:

Drug: THC

Drug: Placebo

Placebo

Placebo Comparator group

Description:

Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.

Treatment:

Drug: THC

Drug: Placebo